Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma
8.5
来源：
Nature
关键字：
siRNA
发布时间：
2025-10-07 03:53
摘要：
The study explores a combination therapy using HDAC inhibitor chidamide and PI3K inhibitor duvelisib for treating p53-mutant diffuse large B-cell lymphoma (DLBCL). The results indicate that this combination significantly induces apoptosis and inhibits tumor growth in preclinical models. Mechanistically, it stabilizes IκBα, suppressing NF-κB activity and autophagy, which are critical for tumor survival. This approach addresses significant unmet needs in treating this aggressive lymphoma subtype, suggesting a promising pathway for clinical application.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.8
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
The combination regimen demonstrated robust induction of apoptosis across multiple p53+ DLBCL cell lines.
This innovative strategy aims to overcome the clinical challenges associated with TP53-mutated DLBCL.
Chidamide-duvelisib coadministration significantly suppresses autophagy and enhances apoptosis.
真实性检查
否
AI评分总结
The study explores a combination therapy using HDAC inhibitor chidamide and PI3K inhibitor duvelisib for treating p53-mutant diffuse large B-cell lymphoma (DLBCL). The results indicate that this combination significantly induces apoptosis and inhibits tumor growth in preclinical models. Mechanistically, it stabilizes IκBα, suppressing NF-κB activity and autophagy, which are critical for tumor survival. This approach addresses significant unmet needs in treating this aggressive lymphoma subtype, suggesting a promising pathway for clinical application.